CLINICAL TRIALS PROFILE FOR GATTEX KIT
✉ Email this page to a colleague
All Clinical Trials for GATTEX KIT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00072839 ↗ | Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease | Completed | Shire | Phase 2 | 2003-11-12 | The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease. |
| NCT00081458 ↗ | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome | Completed | Shire | Phase 3 | 2004-05-25 | The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS). |
| NCT00172185 ↗ | Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) | Completed | Shire | Phase 3 | 2005-01-10 | The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide. |
| NCT00798967 ↗ | Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects | Completed | Nycomed | Phase 3 | 2008-11-25 | Teduglutide is an investigative medicine being evaluated as a possible treatment for people with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar to a protein the body makes. When people have SBS, their bodies do not make enough of the protein and they have trouble getting nutrients and fluids from the food they eat and drink. This study was designed to provide evidence of efficacy, safety, and tolerability of teduglutide 0.05 mg/kg daily in SBS subjects. |
| NCT00798967 ↗ | Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects | Completed | Shire | Phase 3 | 2008-11-25 | Teduglutide is an investigative medicine being evaluated as a possible treatment for people with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar to a protein the body makes. When people have SBS, their bodies do not make enough of the protein and they have trouble getting nutrients and fluids from the food they eat and drink. This study was designed to provide evidence of efficacy, safety, and tolerability of teduglutide 0.05 mg/kg daily in SBS subjects. |
| NCT00819468 ↗ | Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants | Completed | NPS Pharma | Phase 1 | 2007-07-26 | This is a study to compare the pharmacokinetic profile of teduglutide in healthy participants with normal hepatic function with participants who have moderate hepatic impairment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GATTEX KIT
Condition Name
Clinical Trial Locations for GATTEX KIT
Trials by Country
Clinical Trial Progress for GATTEX KIT
Clinical Trial Phase
Clinical Trial Sponsors for GATTEX KIT
Sponsor Name
